Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization EBIAT Leases Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Shares Issued Shares Outstanding Shares Outstanding Shares Repurchased

Ratios

C4 Therapeutics (CCCC) Shares Repurchased (2019 - 2026)

C4 Therapeutics has reported Shares Repurchased over the past 6 years, most recently at $200000.0 for Q1 2026.

For Q1 2026, Shares Repurchased rose 29.03% year-over-year to $200000.0; the TTM value through Mar 2026 reached $238000.0, down 0.83%, while the annual FY2025 figure was $193000.0, 0.52% down from the prior year.
Shares Repurchased for Q1 2026 was $200000.0 at C4 Therapeutics, up from $14000.0 in the prior quarter.
Over five years, Shares Repurchased peaked at $200000.0 in Q1 2026 and troughed at $14000.0 in Q4 2025.
A 4-year average of $87125.0 and a median of $89500.0 in 2023 define the central range for Shares Repurchased.
Biggest five-year swings in Shares Repurchased: soared 431.25% in 2024 and later tumbled 71.76% in 2025.
Year by year, Shares Repurchased stood at $16000.0 in 2023, then soared by 431.25% to $85000.0 in 2024, then crashed by 83.53% to $14000.0 in 2025, then soared by 1328.57% to $200000.0 in 2026.
Business Quant data shows Shares Repurchased for CCCC at $200000.0 in Q1 2026, $14000.0 in Q4 2025, and $24000.0 in Q3 2025.